Supernus Pharmaceuticals (SUPN) PT Raised to $35 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $35.00 (from $33.00) while maintaining an Outperform rating.

The analyst commented, "The Q2 results in the legacy operations (Trokendi/ Oxtellar) were solid, as were the initial partial sales from the WorldMeds CNS/Parkinson's portfolio. The next stage of growth will be driven by both the anticipated '812 non-stimulant ADHD launch later this year & the full integration of the new CNS portfolio. The diversification is here and BD in the fragmented PD marketplace could accelerate."

You May Also Be Interested In

• JD.com, Inc (JD) PT Lowered to $39 at Mizuho
• Applied Materials (AMAT) PT Lowered to $650 at BofA Securities, 'our top semicap pick is LRCX'
• Agora Inc. (API) PT Raised to $6.80 at BofA Securities